



IFW

Docket No. PRD-2110-USANP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : MacDonald et al. Conf. No.: 1638  
Appln. No. : 10/667,096 Art Unit: 1647  
Filed : September 18, 2003 Examiner: B. Bunner  
For : METHODS OF INCREASING PLATELET AND HEMATOPOIETIC  
STEM CELL PRODUCTION

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 12, 2007

\_\_\_\_\_  
(Date of Deposit)

Laura A. Donnelly

(Name of applicant, assignee, or Registered Representative)

/Laura A. Donnelly/

\_\_\_\_\_  
(Signature)

March 12, 2007

\_\_\_\_\_  
(Date of Signature)

MAIL STOP GROUP ART UNIT 1647  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure  
Statements mailed on January 23, 2004, March 24, 2004 and May  
18, 2006.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-  
identified application is hereby disclosed. Inclusion of  
information in this statement is not to be construed as an  
admission that this information is material as that term is  
defined in 37 C.F.R. §1.56(b).

03/16/2007 EAYALEW1 00000002 100750 10667056

01 FC:1806 180.00 DR

103

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☒ Please charge Deposit Account No. 10-0750/PRD-2110-USANP/LAD the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-2110-USANP/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

---

Laura A. Donnelly  
Reg. No. 38,435  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1729  
DATED: March 12, 2007

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-2110-USANP/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

---

Laura A. Donnelly  
Reg. No. 38,435  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1729  
DATED: March 12, 2007



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE -

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 8

Application Number	10/667,096
Filing Date	September 18, 2003
First Named Inventor	Brian R. MacDonald
Group Art Unit	1647
Examiner Name	Bridget E. Bunner.
Attorney Docket Number	PRD-2110-USANP

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,143,854		Pirung et al.	09-01-1992	
		5,270,170		Schatz et al.	12-14-1993	
		5,326,558		Turner et al.	07-05-1994	
		5,338,665		Schatz et al.	08-16-1994	
		5,384,331		Kogan et al.	01-24-1995	
		5,358,934		Borovsky et al.	10-25-1994	
		5,141,851		Brown et al.	08-25-1992	
		5,411,942		Widmer et al.	05-02-1995	
		5,869,451		Dower et al.	02-09-1999	
		5,932,546		Barrett et al.	08-03-1999	
				(continued on page 2)		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
		WO	95/21919	A2	Kirin Brewery Company, Ltd.	08-17-1995		
		WO	96/40750	A1	Glaxo Group Ltd.	12-19-1996		
		WO	98/25965	A2	Glaxo Group Ltd.	06-18-1998		
					(continued on page 2)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 8

Application Number	10/667,096
Filing Date	September 18, 2003
First Named Inventor	Brian R. MacDonald
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	PRD-2110-USANP

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		6,060,052		Murray et al.	05-09-2000	
		6,083,913		Dower et al.	07-04-2000	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		WO	90/15070	A1	Affymax Technologies N.V.	12-13-1990		
		WO	91/07988	A1	Amgen Inc.	06-13-1991		
		WO	91/08752	A1	Amrad Corporation Limited	06-27-1991		
		WO	93/25221	A1	Alkermes Controlled Therapeutics, Inc.	12-23-1993		
		WO	95/11922	A1	Affymax Technologies N.V.	05-04-1995		
		WO	95/18858	A1	Genentech, Inc.	07-13-1995		
					(continued on page 3)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 8

Application Number	10/667,096
Filing Date	September 18, 2003
First Named Inventor	Brian R. MacDonald
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	PRD-2110-USANP

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		WO	95/21626	A1	University of Washington	08-17-1995		
		WO	95/21920	A1	Zymogenetics, Inc.	08-17-1995		
		WO	95/28907	A2	Rosenberg et al.	11-02-1995		
		EP	0 668 352	A1	Kirin Brewery Company, Ltd.	02-14-1995		
		EP	0 675 201	A1	Amgen Inc.	03-30-1995		
					(continued on page 4)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



<p><b>Substitute for form 1449A/PTO</b></p> <p style="text-align: center; font-size: 1.2em; font-weight: bold;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center; font-size: 0.8em;">(use as many sheets as necessary)</p> <p style="text-align: center; font-weight: bold;">Sheet 4 of 8</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;"><i>Application Number</i></td> <td style="padding: 2px;">10/667,096</td> </tr> <tr> <td style="padding: 2px;"><i>Filing Date</i></td> <td style="padding: 2px;">September 18, 2003</td> </tr> <tr> <td style="padding: 2px;"><i>First Named Inventor</i></td> <td style="padding: 2px;">Brian R. MacDonald</td> </tr> <tr> <td style="padding: 2px;"><i>Group Art Unit</i></td> <td style="padding: 2px;">1647</td> </tr> <tr> <td style="padding: 2px;"><i>Examiner Name</i></td> <td style="padding: 2px;">Bridget E. Bunner</td> </tr> <tr> <td style="padding: 2px;"><i>Attorney Docket Number</i></td> <td style="padding: 2px;">PRD-2110-USANP</td> </tr> </table>	<i>Application Number</i>	10/667,096	<i>Filing Date</i>	September 18, 2003	<i>First Named Inventor</i>	Brian R. MacDonald	<i>Group Art Unit</i>	1647	<i>Examiner Name</i>	Bridget E. Bunner	<i>Attorney Docket Number</i>	PRD-2110-USANP
<i>Application Number</i>	10/667,096												
<i>Filing Date</i>	September 18, 2003												
<i>First Named Inventor</i>	Brian R. MacDonald												
<i>Group Art Unit</i>	1647												
<i>Examiner Name</i>	Bridget E. Bunner												
<i>Attorney Docket Number</i>	PRD-2110-USANP												

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		EP	0 690 127	A1	Amgen Inc.	01-03-1996		
		GB	2 285 446	A	Genentech Inc.	07-12-1995		
		WO	96/17062	A1	Zymogenetics, Inc.	06-06-1996		
		WO	96/17067	A1	Zymogenetics, Inc.	06-06-1996		

<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%; padding: 2px;">Examiner Signature</td> <td style="width: 40%; height: 20px;"></td> <td style="width: 15%; padding: 2px;">Date Considered</td> <td style="width: 30%; height: 20px;"></td> </tr> </table>	Examiner Signature		Date Considered	
Examiner Signature		Date Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 8

Application Number	10/667,096
Filing Date	September 18, 2003
First Named Inventor	Brian R. MacDonald
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	PRD-2110-USANP

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

	Barker et al. "Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics", J. Med. Chem. Vol. 35, pp. 2040-2048 (1992).	
	Bartley et al. "Identification and Cloning of a Megakaryocyte Growth and Development Factor That Is a Ligand for the Cytokine Receptor Mpl", Cell, Vol. 77, pp. 1117-1124 (1994).	
	Basser et al., "Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer", Blood, Vol. 89, No. 9, pp. 3118-3128 (1997).	
	Bazan, "Structural design and molecular evolution of a cytokine receptor superfamily", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 6934-6938 (1990).	
	Berger et al. "A New Method for the Synthesis of Optically Active $\alpha$ -Amino Acids and Their N <sup>α</sup> Derivatives via Acylamino Malonates", J. Org. Chem., Vol. 38, No. 3, pp. 457-460 (1973).	
	Bernard et al. "The Oncogene V-MPL, A Putative Truncated Cytokine Receptor Which Immortalizes Hematopoietic Progenitors", L'Inserm, Vol. 33, pp. 145-146 (1991).	
	Caras et al. "Signal Peptide for Protein Secretion Directing Glycophospholipid Membrane Anchor Attachment", Science, Vol. 243, pp. 1196-1198 (1989).	
	Cwirla et al. "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 6378-6382 (1990).	
	Daumas et al. "Gramicidin A analogs: influence of the substitution of the tryptophans by naphthylalanines", Biochimie, Vol. 71, pp. 77-81 (1989).	
	de Sauvage et al. "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand", Nature, Vol. 369, pp. 533-538 (1994).	
	Dexter et al. "Growth of Factor-Dependent Hemopoietic Precursor Cell Lines", J. Exp. Med., Vol. 152, pp. 1036-1047 (1980).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 8

<b>Application Number</b>	10/667,096
<b>Filing Date</b>	September 18, 2003
<b>First Named Inventor</b>	Brian R. MacDonald
<b>Group Art Unit</b>	1647
<b>Examiner Name</b>	Bridget E. Bunner
<b>Attorney Docket Number</b>	PRD-2110-USANP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Dower et al. "The Search for Molecular Diversity (II): Recombinant and Synthetic Randomized Peptide Libraries", Annual Reports in Medicinal Chemistry, Vol. 26, pp. 271-280 (1991).	
		Dower et al. "High efficiency transformation of <i>E.coli</i> by high voltage electroporation", Nucleic Acids Research, Vol. 16, No. 13, pp. 6127-6145 (1988).	
		Evans et al. "Design of Nonpeptidic Ligands for a Peptide Receptor: Cholecystokinin Antagonists", J. Med. Chem, Vol. 30, pp. 1229-1239 (1987).	
		Fauchère "Elements for the Rational Design of Peptide Drugs", Advances in Drug Research, Vol. 15, pp. 29-69 (1986).	
		Fodor et al. "Light-Directed, Spatially Addressable Parallel Chemical Synthesis", Science, Vol. 251, pp. 767-773 (1991).	
		Gante "Peptidomimetics-Tailored Enzyme Inhibitors", Angen. Chem. Int. Ed. Engl., Vol. 33, pp. 1699-1720 (1994).	
		Harker "Kinetics of Thrombopoiesis", The Journal of Clinical Investigation, Vol. 47, pp. 458-465 (1968).	
		Kato et al., "Purification and Characterization of Thrombopoietin <sup>1</sup> ", J. Biochem. Vol. 118, No. 1, pp. 229-236 (1995).	
		Kaushansky et al., "Thrombopoietin Expands Erythroid Progenitors, Increases Red Cell Production, and Enhances Erythroid Recovery after Myelosuppressive Therapy", J. Clin. Invest., Vol 96, pp. 1683-1687 (1995).	
		Kaushansky et al., "Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice", Experimental Hematology, Vol. 24, pp. 265-269 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 8

<b>Application Number</b>	10/667,096
<b>Filing Date</b>	September 18, 2003
<b>First Named Inventor</b>	Brian R. MacDonald
<b>Group Art Unit</b>	1647
<b>Examiner Name</b>	Bridget E. Bunner
<b>Attorney Docket Number</b>	PRD-2110-USANP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Kojima et al. "Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA*", The Journal of Biological Chemistry, Vol. 270, No. 37, pp. 21984-21990 (1995).	
		Kuter et al. "The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production", Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 11104-11108 (1994).	
		McDonald. "Thrombopoietin, Its Biology, Clinical Aspects, and Possibilities" The American Journal of Pediatric Hematology/Oncology, Vol. 14, No. 1, pp. 8-21 (1992).	
		Metcalf. "Thrombopoietin - at last", Nature, Vol. 369, pp. 519-520 (1994).	
		Methia "Oligodeoxynucleotides Antisense to the Proto-oncogene <i>c-mpl</i> Specifically Inhibit in Vitro Megakaryocytopoiesis", Blood, Vol. 82, No. 5, pp. 1395-1401 (1993).	
		Mosmann. "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays", Journal of Immunological Methods, Vol. 65, pp. 55-63 (1983).	
		Neelis et al. "Prevention of Thrombocytopenia by Thrombopoietin in Myelosuppressed Rhesus Monkeys Accompanied by Prominent Erythropoietic Stimulation and Iron Depletion", Blood, No. 90, No. 1, pp. 58-63 (1997).	
		Nestor et al. "Synthesis and Biological Activity of Some Very Hydrophobic Superagonist Analogues of Luteinizing Hormone-Releasing Hormone <sup>1</sup> ", J. Med. Chem., Vol. 25, pp. 795-801 (1982).	
		Or et al. "Cysteine Alkylation in Unprotected Peptides: Synthesis of a Carbavasopressin Analogue by Intramolecular Cysteine Alkylation", J. Org. Chem., Vol. 56, pp. 3146-3149 (1991).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) <b>Sheet 8 of 8</b>	<b>Application Number</b>	10/667,096
	<b>Filing Date</b>	September 18, 2003
	<b>First Named Inventor</b>	Brian R. MacDonald
	<b>Group Art Unit</b>	1647
	<b>Examiner Name</b>	Bridget E. Bunner
	<b>Attorney Docket Number</b>	PRD-2110-USANP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Papayannopoulou et al. "Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy", Experimental Hematology, Vol. 24, pp. 660-669 (1996).	
		Porter et al. "Synthesis, resolution and characterization of ring substituted phenylalanines and tryptophans", International Journal of Peptide and Protein Research, Vol. 30, No. 1 (Abstract).	
		Souyri et al. "A Putative Truncated Cytokine Receptor Gene Transduced by the Myeloproliferative Leukemia Virus Immortalizes Hematopoietic Progenitors", Cell, Vol. 63, pp. 1137-1147 (1990).	
		Veber et al. "The design of metabolically-stable peptide analogs", Trends in Neurosciences (TINS), pp. 392-396 (1985).	
		Vigon et al. "Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 5640-5644 (1992).	
		Wada et al. "Characterization of the Truncated Thrombopoietin Variants", Biochemical and Biophysical Research Communications, Vol. 213, No. 3, pp. 1091-1098 (1995).	
		Wang et al. "Design and synthesis of novel $\chi^2$ -constrained phenylalanine, naphthylalanine, and tryptophan analogues and their use in biologically active melanotropin peptides", Tetrahedron, Vol. 58, pp. 7365-7374 (2002).	
		Wendling et al. "The Oncogene V-MPL, A Putative Truncated Cytokine Receptor Which Immortalizes Hematopoietic Progenitors", L'Inserm, pp. 145-146 (1992).	
		Wendling et al. "c-Mpl ligand is a humoral regulator of megakaryocytopoiesis", Nature, pp. 571-574 (1994).	
		Yabe et al. "Analogues of Luteinizing Hormone-Releasing Hormone with Modification in Position 3 <sup>1</sup> ", Chem. Pharm. Bull., pp. 3149-3157 (1976).	
		Yabe et al. "Synthesis and Biological Activity of Tetragastrin Analogues modifying the Tryptophan Residue <sup>1</sup> ", Chem. Pharm. Bull., Vol. 25, No. 10, pp. 2731-2734 (1977).	
		Yabe et al. "Synthesis and Biological Activity of Somatostatin Analogues modified at the Tryptophan Residue <sup>1</sup> ", Chem. Pharm. Bull., Vol. 26, No. 3, pp. 993-997 (1978).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.